INIS
breasts
100%
cancer
100%
patients
83%
chemotherapy
36%
therapy
22%
netherlands
21%
metastases
19%
receptors
17%
diseases
15%
tumors
14%
hormones
13%
women
11%
data
10%
nmr imaging
10%
comparative evaluations
9%
lymph nodes
9%
risks
8%
cost
8%
positron computed tomography
7%
tamoxifen
7%
values
6%
hazards
6%
ovaries
5%
failures
5%
fluorine 18
5%
humans
5%
Keyphrases
Breast Cancer Patients
42%
Netherlands
22%
Advanced Breast Cancer
21%
Breast Cancer
18%
Neoadjuvant Chemotherapy
15%
Chemotherapy
14%
Metastatic Breast Cancer
10%
Cancer Registry
9%
Hormone Receptor-positive
9%
Pathological Complete Response
9%
Dutch
9%
Anastrozole
7%
Overall Survival
7%
Early Breast Cancer
7%
Trastuzumab
7%
Everolimus
7%
HER2-positive Advanced Breast Cancer
6%
Human Epidermal Growth Factor Receptor 2 (HER2)
6%
Hormone Receptor
6%
Treatment Choice
6%
HER2+
6%
Disease-free Survival
6%
Chemotherapy-induced
5%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
5%
Patients with Breast Cancer
5%
Sentinel Lymph Node Biopsy
5%
Hazard Ratio
5%
Node-positive Breast Cancer
5%
PET-MRI
5%
Exemestane
5%
Medicine and Dentistry
Breast Cancer
72%
Chemotherapy
17%
Hormone Receptor
12%
Neoadjuvant Chemotherapy
11%
Metastatic Breast Cancer
10%
Neoplasm
9%
Anastrozole
7%
Systemic Therapy
7%
Overall Survival
7%
Cancer Registry
7%
Disease Free Survival
7%
Axillary Lymph Node
5%
Ovary Function
5%
Tamoxifen
5%
Disease
5%
Fluorodeoxyglucose F 18
5%
Hormone Therapy
5%
Positron Emission Tomography - Magnetic Resonance Imaging
5%
Everolimus
5%